David R. Sibley
Affiliations: | National Institutes of Health, Bethesda, MD |
Area:
DopamineGoogle:
"David Sibley"Mean distance: 14.77 (cluster 11) | S | N | B | C | P |
Parents
Sign in to add mentor| Arthur Stephen Dahms | grad student | 1975-1977 | San Diego State University/USCD (Chemistry Tree) |
| Ian Creese | grad student | 1978-1982 | UCSD |
| Robert J. Lefkowitz | post-doc | 1983-1987 | Duke |
Children
Sign in to add trainee| Nora Madaras | research assistant | 2021-2023 | NIH |
| Amy E. Moritz | post-doc | NIH (Chemistry Tree) | |
| Kathryn D. Luderman | post-doc | 2014- | NIH |
| Emmanuel O. Akano | post-doc | 2016- | NIH |
| Marta Sanchez Soto | post-doc | 2017- | NIH |
| Ana Lucia Marques Ventura | post-doc | 1994-1996 | NIH |
| Lisa A. Hazelwood | post-doc | 2004-2010 | NIH |
| R Benjamin Free | research scientist | 2003- | NIH |
| David M. Cabrera | research scientist | 2000-2009 | NIH |
| Marilyn M. Day | research scientist | 2016-2018 | NIH |
| Blair K. A. | research scientist | 2017-2018 | NIH |
| Caroline A Cuoco | research scientist | 2017-2019 | NIH |
| Kayla A. Schardien | research scientist | 2018-2020 | NIH |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Sibley DR, Nilson AN, Moritz AE, et al. (2023) Dopamine receptor divergence revealed using a common ligand. Trends in Pharmacological Sciences |
| Enriquez-Traba J, Yarur-Castillo HE, Flores RJ, et al. (2023) Dissociable control of motivation and reinforcement by distinct ventral striatal dopamine receptors. Biorxiv : the Preprint Server For Biology |
| Moritz AE, Madaras NS, Rankin ML, et al. (2023) Delineation of G Protein-Coupled Receptor Kinase Phosphorylation Sites within the D Dopamine Receptor and Their Roles in Modulating β-Arrestin Binding and Activation. International Journal of Molecular Sciences. 24 |
| Free RB, Nilson AN, Boldizsar NM, et al. (2022) Identification and Characterization of ML321: A Novel and Highly Selective D Dopamine Receptor Antagonist with Efficacy in Animal Models That Predict Atypical Antipsychotic Activity. Acs Pharmacology & Translational Science. 6: 151-170 |
| Aslanoglou D, Bertera S, Friggeri L, et al. (2022) Dual pancreatic adrenergic and dopaminergic signaling as a therapeutic target of bromocriptine. Iscience. 25: 104771 |
| Free RB, Cuoco CA, Xie B, et al. (2021) Pharmacological characterization of the imipridone anti-cancer drug ONC201 reveals a negative allosteric mechanism of action at the D dopamine receptor. Molecular Pharmacology |
| Sibley DR, Luderman KD, Free RB, et al. (2021) Novel Cryo-EM structures of the D1 dopamine receptor unlock its therapeutic potential. Signal Transduction and Targeted Therapy. 6: 205 |
| Aslanoglou D, Bertera S, Sánchez-Soto M, et al. (2021) Dopamine regulates pancreatic glucagon and insulin secretion via adrenergic and dopaminergic receptors. Translational Psychiatry. 11: 59 |
| Luderman KD, Jain P, Benjamin Free R, et al. (2020) Development of Pyrimidone D1 Dopamine Receptor Positive Allosteric Modulators. Bioorganic & Medicinal Chemistry Letters. 127696 |
| Moritz AE, Bonifazi A, Guerrero AM, et al. (2020) Evidence for a stereoselective mechanism for bitopic activity by extended-length antagonists of the D3 dopamine receptor. Acs Chemical Neuroscience |